These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 11986036)

  • 1. Adverse environmental exposures in pregnancy: teratology in adolescent medicine practice.
    Seaver LH
    Adolesc Med; 2002 Jun; 13(2):269-91, vi. PubMed ID: 11986036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors.
    Brent RL
    Pediatrics; 2004 Apr; 113(4 Suppl):957-68. PubMed ID: 15060188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical teratology.
    McCormack MK
    Am Fam Physician; 1983 Dec; 28(6):153-61. PubMed ID: 6650332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproic acid in pregnancy: how much are we endangering the embryo and fetus?
    Ornoy A
    Reprod Toxicol; 2009 Jul; 28(1):1-10. PubMed ID: 19490988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Counseling adolescents about environmental teratogens.
    Williams JK
    Pediatr Nurs; 1986; 12(4):292-5, 304. PubMed ID: 3637772
    [No Abstract]   [Full Text] [Related]  

  • 6. Teratogenically induced fetal anomalies.
    Hoyme HE
    Clin Perinatol; 1990 Sep; 17(3):547-67. PubMed ID: 2225687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Principles of human teratology: drug, chemical, and infectious exposure.
    Wilson RD; ;
    J Obstet Gynaecol Can; 2007 Nov; 29(11):911-917. PubMed ID: 17977495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Wilson's principles--a base of modern teratology].
    Burdan F; Bełzek A; Szumiło J; Dudka J; Korobowicz A; Tokarska E; Klepacz L; Bełzek M; Klepacz R
    Pol Merkur Lekarski; 2006 Mar; 20(117):358-61. PubMed ID: 16780275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk minimization practices for pregnancy prevention: understanding risk, selecting tools.
    Uhl K; Trontell A; Kennedy D
    Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):337-48. PubMed ID: 16953517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teratogens associated with congenital contractures in humans and in animals.
    Hall JG; Reed SD
    Teratology; 1982 Apr; 25(2):173-91. PubMed ID: 7101197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of known environmental teratogens: drugs and chemicals.
    Beckman DA; Brent RL
    Clin Perinatol; 1986 Sep; 13(3):649-87. PubMed ID: 3533369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse pregnancy outcome: sensitive periods, types of adverse outcomes, and relationships with critical exposure periods.
    Kochenour NK
    Prog Clin Biol Res; 1984; 160():229-35. PubMed ID: 6382329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Environmental exposures and adverse pregnancy outcomes: a review of the science.
    Stillerman KP; Mattison DR; Giudice LC; Woodruff TJ
    Reprod Sci; 2008 Sep; 15(7):631-50. PubMed ID: 18836129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic basis of susceptibility to teratogen induced birth defects.
    Wlodarczyk BJ; Palacios AM; Chapa CJ; Zhu H; George TM; Finnell RH
    Am J Med Genet C Semin Med Genet; 2011 Aug; 157C(3):215-26. PubMed ID: 21766441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teratogenic exposures.
    Običan S; Scialli AR
    Am J Med Genet C Semin Med Genet; 2011 Aug; 157C(3):150-69. PubMed ID: 21766437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human teratogens: update 2010.
    Holmes LB
    Birth Defects Res A Clin Mol Teratol; 2011 Jan; 91(1):1-7. PubMed ID: 21254353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perinatal psychoactive drug use: effects on gender, development, and function in offspring.
    Martin JC
    Nebr Symp Motiv; 1984; 32():227-66. PubMed ID: 6398856
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse drug reactions in utero: perspectives on teratogens and strategies for the future.
    Mitchell AA
    Clin Pharmacol Ther; 2011 Jun; 89(6):781-3. PubMed ID: 21593753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.
    Crofts F; Rohatagi S; Pino M; DeLise B; Zhang J; Nguyen M; Guittin P; Barbellion S; Brunel P; Hofmann T; Schmidt J; Wong M; Lockey P; Lerman S; Clark R
    Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):69-79. PubMed ID: 15098200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmarketing surveillance for human teratogenicity: a model approach.
    Chambers CD; Braddock SR; Briggs GG; Einarson A; Johnson YR; Miller RK; Polifka JE; Robinson LK; Stepanuk K; Lyons Jones K
    Teratology; 2001 Nov; 64(5):252-61. PubMed ID: 11745831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.